DESIGN FOR THE COLON CANCER INHIBITORS TARGETING THYMIDYLATE KINASE BY USING INSILICO STUDIES

Authors

  • MOHD ABDUL BAQI Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India https://orcid.org/0009-0000-3711-3568
  • KOPPULA JAYANTHI Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India https://orcid.org/0009-0003-9358-4278
  • RAMAN RAJESHKUMAR Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ijap.2024v16i3.50079

Keywords:

Thymidylate kinase (TMK), Molecular docking, Molecular dynamics simulations, MM-GBSA, HTVS, ADME, cancer, HaTMK

Abstract

Objective: Thymidylate Kinase (TMK) plays a crucial role in bacterial DNA synthesis by catalyzing the phosphorylation of Deoxythymidine Monophosphate (dTMP) to form Deoxythymidine Diphosphate (dTDP). Consequently, this enzyme emerges as a promising target for developing novel anti-cancer drugs. However, no anti-cancer drugs have been reported for this target until now.

Methods: Ligands obtained from Benzylidene derivatives were examined for their potency by using molecular docking by glide module, Qikprop screening of Absorption, Distribution, Metabolism, and Excretion (ADME) study, and prime Molecular Mechanics in Generalized Bond Surface Area study (MM-GBSA) by binding free energy. Hereafter, a Molecular Dynamic (MD) simulation was performed at 100 ns to assess the stability of the potential ligand as a Human TMK (HaTMK) inhibitor.

Results: These ten molecules showed good binding affinity and hydrogen and hydrophobic bond interactions with Arg150, Phe42, and Phe72 in the HaTMK enzyme (PDB id:1E2D). Among them, trichloro-6-(((4-hydroxyphenyl)imino)methyl)phenol molecule had a high XP-docking score of (−7.87 kcal/mol), based on extra-precision data. Prime MM-GBSA studies also showed promising binding affinities i.e., ΔBind (-34.59 kcal/mol), ΔLipo (-13.92 kcal/mol), and ΔVdW (-34.42 kcal/mol). Arg76 and Phe72 residues maintained constant interactions with the ligand during Molecular Dynamics (MD) simulation. This ligand showed a potential binding affinity for the TMK target.

Conclusion: The trichloro-6-(((4-hydroxyphenyl)imino)methyl)phenol ligand has active sites namely benzene ring, benzylidene, and oxygen group which actively participate in interaction with the protein of HaTMK, thus indicating good potential activity as the inhibitor of HaTMK to treat colon cancer.

Downloads

Download data is not yet available.

References

Shewach DS, Kuchta RD. Introduction to Cancer Chemotherapeutics. Chem Rev. 2009 Jul 8;109(7):2859–61. doi: 10.1021/cr900208x. PMID: 19583428

Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. Journal of cancer research and practice. 2017;4(4):127–9. doi: 10.1016/j.jcrpr.2017.07.001.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021 May;71(3):209–49. doi: 10.3322/caac.21660. PMID: 33538338

Labianca R, Beretta G, Gatta G, de Braud F, Wils J. Colon cancer. Critical reviews in oncology/hematology. 2004;51(2):145–70. doi: 10.1016/j.critrevonc.2004.03.003. PMID: 15276177

Munier‐Lehmann H, Chaffotte A, Pochet S, Labesse G. Thymidylate kinase of Mycobacterium tuberculosis: A chimera sharing properties common to eukaryotic and bacterial enzymes. Protein Science. 2001 Jun;10(6):1195–205. doi: 10.1110/ps.45701. PMID: 11369858

Ostermann N, Schlichting I, Brundiers R, Konrad M, Reinstein J, Veit T, Goody RS, Lavie

A. Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate. Structure. 2000;8(6):629–42. doi: 10.1016/s0969-2126(00)00149-0. PMID: 10873853

Kotaka M, Dhaliwal B, Ren J, Nichols CE, Angell R, Lockyer M, Hawkins AR, Stammers DK. Structures of S. aureus thymidylate kinase reveal an atypical active site configuration and an intermediate conformational state upon substrate binding. Protein Science. 2006;15(4):774–84. doi: 10.1110/ps.052002406. PMID: 16522804

Ostermann N, Schlichting I, Brundiers R, Konrad M, Reinstein J, Veit T, Goody RS, Lavie

A. Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate. Structure. 2000;8(6):629–42. doi: 10.1016/s0969-2126(00)00149-0. PMID: 10873853

Amer HH, Ali OM, Salama AA, El-gendy MS, Houssin OK. Synthesis of some new 1, 3, 4- oxadiazole derivatives bearing sugars and α-aminophosphonate derived from 4-nitrophenol as anticancer agents. National Journal of Physiology, Pharmacy and Pharmacology. 2018;8(9):1275–1275. doi: 10.5455/njppp.2018.8.0416408052018.

Jerez LB, Oyervides LR, Gómez A, Jiménez-Pérez VM, Muñoz-Flores BM. Electrochemical metallization with Sn of (E)-4-((4-nitrobenzylidene) amino) phenol in non-aqueous media: Characterization and biological activity of the organotin compound. Int J Electrochem Sci. 2016;11:45–53.

James JP, Aiswarya TC, Priya S, Jyothi D, Dixit SR. Structure based multitargeted molecular docking analysis of pyrazole-condensed heterocyclics against lung cancer. Int J App Pharm. 2021;3(6):157–69. doi:10.22159/ijap.2021v13i6.42801.

Dar AM, Mir S. Molecular docking: approaches, types, applications and basic challenges. J Anal Bioanal Tech. 2017;8(2):1–3.

Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des.2013 Mar;27(3):221–34. doi: 10.1007/s10822-013-9644-8. PMID: 23579614

Sukumaran S, M M, S S, B A, S S, S ST. Insilico analysis of acridone against TNF-α and PDE4 targets for the treatment of psoriasis. International Journal of Research in Pharmaceutical Sciences. 2020 Dec 18;11(4):7790–8.

Dunkel M, Fullbeck M, Neumann S, Preissner R. SuperNatural: a searchable database of available natural compounds. Nucleic acids research. 2006;34(suppl_1):D678–83. doi: 10.1093/nar/gkj132. PMID: 16381957

Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B, Shaw DE, Friesner RA. A hierarchical approach to all‐atom protein loop prediction. Proteins. 2004 May;55(2):351–67. doi:10.1002/prot.10613. PMID: 15048827

Dhawale S, Gawale S, Jadhav A, Gethe K, Raut P, Hiwarale N, Bhosale P, Tapadiya AG. In silico approach targeting polyphenol as Fabh inhibitor in bacterial infection. International Journal of Pharmacy and Pharmaceutical Sciences. 2022;14(11):25–30. doi: 10.22159/ijpps.2022v14i11.45816

Martyna GJ, Tuckerman ME, Tobias DJ, Klein ML. Explicit reversible integrators for extended systems dynamics. Molecular Physics. 1996;87(5):1117–57. doi: 10.1080/00268979600100761.

Guo Z, Mohanty U, Noehre J, Sawyer TK, Sherman W, Krilov G. Probing the α‐Helical Structural Stability of Stapled p53 Peptides: Molecular Dynamics Simulations and Analysis. Chem Biol Drug Des. 2010 Apr;75(4):348–59. doi:10.1111/j.1747-0285.2010.00951.x. PMID: 20331649

Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. The Journal of chemical physics. 1995;103(19):8577–93. doi: 10.1063/1.470117.

Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, Kaus JW, Cerutti DS, Krilov G, Jorgensen WL, Abel R, Friesner RA. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J Chem Theory Comput. 2016 Jan 12;12(1):281–96. doi: 10.1021/acs.jctc.5b00864. PMID: 26584231

Martyna GJ, Tobias DJ, Klein ML. Constant pressure molecular dynamics algorithms. The Journal of Chemical Physics. 1994 Sep 1;101(5):4177–89. doi:10.1063/1.467468.

Badavath VN, Sinha BN, Jayaprakash V. Design, in-silico docking and predictive ADME properties of novel pyrazoline derivatives with selective human MAO inhibitory activity. Int J Pharm Pharm Sci. 2015;7:277–82.

Chen YH, Hsu HY, Yeh MT, Chen CC, Huang CY, Chung YH, Chang ZF, Kuo WC, Chan NL, Weng JH. Chemical inhibition of human thymidylate kinase and structural insights into the phosphate binding loop and ligand-induced degradation. Journal of Medicinal Chemistry. 2016;59(21):9906–18. doi: 10.1021/acs.jmedchem.6b01280. PMID: 27748121

Ajmal A, Mahmood A, Hayat C, Hakami MA, Alotaibi BS, Umair M, Abdalla AN, Li P, He P, Wadood A. Computer-assisted drug repurposing for thymidylate kinase drug target in monkeypox virus. Frontiers in Cellular and Infection Microbiology. 2023;13:618. doi: 10.3389/fcimb.2023.1159389. PMID: 37313340

Published

11-03-2024

How to Cite

BAQI, M. A., JAYANTHI, K., & RAJESHKUMAR, R. (2024). DESIGN FOR THE COLON CANCER INHIBITORS TARGETING THYMIDYLATE KINASE BY USING INSILICO STUDIES. International Journal of Applied Pharmaceutics, 16(3). https://doi.org/10.22159/ijap.2024v16i3.50079

Issue

Section

Original Article(s)